J Whooley

1 month ago | medicalindependent.ie | Dawn O'Shea - |Dawn O'Shea |Priscilla Lynch |J Whooley

Reference: April 2025 | Issue 4 | Vol 11 | Page 41 Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumour proportion score (TPS) ≥50 per cent. However, real-world data on its long-term efficacy remain sparse.